Reyvow, Rayvow(lasmiditan)
Rayvow, Reyvow (lasmiditan) is a small molecule pharmaceutical. Lasmiditan was first approved as Reyvow on 2020-01-31. It is used to treat migraine with aura and migraine without aura in the USA. It has been approved in Europe to treat migraine disorders. It is known to target 5-hydroxytryptamine receptor 1F.
Download report
Favorite
FDA Novel Drug Approvals 2019
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
---|---|
nervous system diseases | D009422 |
Trade Name
FDA
EMA
Reyvow
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Lasmiditan succinate
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
REYVOW | Eli Lilly | N-211280 RX | 2020-01-31 | 2 products, RLD, RS |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
---|---|---|
reyvow | Export only | 2023-01-09 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
migraine with aura | EFO_0005295 | D020325 | G43.1 |
migraine without aura | EFO_0005296 | D020326 | G43.0 |
Agency Specific
FDA
EMA
Expiration | Code | ||
---|---|---|---|
LASMIDITAN SUCCINATE, REYVOW, ELI LILLY AND CO | |||
2025-01-31 | NCE |
HCPCS
No data
Clinical
Clinical Trials
33 clinical trials
View more details
![](https://www.pharmakb.com/hubfs/raw_assets/public/ccd-theme/images/generated-html-images/trials-plot.png)
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Migraine disorders | D008881 | EFO_0003821 | G43 | 6 | 3 | 5 | — | — | 14 |
Indications Phases 2
No data
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | 15 | — | — | — | — | 15 | ||
Recreational drug use | D000084783 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | LASMIDITAN |
INN | lasmiditan |
Description | Lasmiditan, sold under the brand name Reyvow, is a medication used for the acute (active but short-term) treatment of migraine with or without aura (a sensory phenomenon or visual disturbance) in adults. It is not useful for prevention. It is taken by mouth.
|
Classification | Small molecule |
Drug class | antimigraine, serotonin 5-HT1 receptor agonists |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CN1CCC(C(=O)c2cccc(NC(=O)c3c(F)cc(F)cc3F)n2)CC1 |
Identifiers
PDB | — |
CAS-ID | 439239-90-4 |
RxCUI | — |
ChEMBL ID | CHEMBL3039520 |
ChEBI ID | — |
PubChem CID | 11610526 |
DrugBank | DB11732 |
UNII ID | 760I9WM792 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
HTR1F
HTR1F
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
![](https://www.pharmakb.com/hubfs/raw_assets/public/ccd-theme/images/generated-html-images/top-terms-plot.png)
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 302 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
![](https://www.pharmakb.com/hubfs/raw_assets/public/ccd-theme/images/generated-html-images/top-adverse-reactions-plot.png)
Mock data
Subscribe for the real data
Subscribe for the real data
2,421 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more